{"name":"Ansun Biopharma, Inc.","slug":"ansun-biopharma-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"immunology","drugs":[{"name":"DAS181","genericName":"DAS181","slug":"das181","indication":"COVID-19 (SARS-CoV-2 infection)","status":"phase_3"},{"name":"DAS181 COVID-19","genericName":"DAS181 COVID-19","slug":"das181-covid-19","indication":"COVID-19 (moderate to severe disease)","status":"phase_3"},{"name":"DAS181 OL","genericName":"DAS181 OL","slug":"das181-ol","indication":"Respiratory viral infections (influenza, COVID-19, other respiratory viruses)","status":"phase_3"},{"name":"DAS181-F02 Dry Powder in Bulk","genericName":"DAS181-F02 Dry Powder in Bulk","slug":"das181-f02-dry-powder-in-bulk","indication":"Treatment of RSV infections","status":"phase_2"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"DAS181-F04 formulation","genericName":"DAS181-F04 formulation","slug":"das181-f04-formulation","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"DAS181-F04 formulation","genericName":"DAS181-F04 formulation","slug":"das181-f04-formulation","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"DAS181","genericName":"DAS181","slug":"das181","phase":"phase_3","mechanism":"DAS181 is a recombinant fusion protein that blocks viral entry by binding to the DPP4 receptor on host cells, preventing respiratory viruses from infecting cells.","indications":["COVID-19 (SARS-CoV-2 infection)","MERS-CoV infection"],"catalyst":""},{"name":"DAS181 COVID-19","genericName":"DAS181 COVID-19","slug":"das181-covid-19","phase":"phase_3","mechanism":"DAS181 is a recombinant fusion protein that blocks SARS-CoV-2 entry into human cells by targeting the ACE2 receptor on the cell surface.","indications":["COVID-19 (moderate to severe disease)"],"catalyst":""},{"name":"DAS181 OL","genericName":"DAS181 OL","slug":"das181-ol","phase":"phase_3","mechanism":"DAS181 is a recombinant fusion protein that blocks viral entry by presenting a soluble receptor domain that captures and neutralizes respiratory viruses.","indications":["Respiratory viral infections (influenza, COVID-19, other respiratory viruses)"],"catalyst":""},{"name":"DAS181-F02 Dry Powder in Bulk","genericName":"DAS181-F02 Dry Powder in Bulk","slug":"das181-f02-dry-powder-in-bulk","phase":"phase_2","mechanism":"DAS181-F02 Dry Powder in Bulk is a fusion protein that targets the sialic acid-binding immunoglobulin-like lectin 9 (Siglec-9) receptor.","indications":["Treatment of RSV infections"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi_AFBVV95cUxNVXpCV25oMmg5aTBBVVZ2cGd1OG9aLUR0aTJJQ2ZHeXQ2TWdHU0gweVlLZ2dXbmVhLXlCaG55X1d2M18yT1J2bk5QbEtXY0JoYWZtbmVrWV96MHVBcW4yOWNaMDhVbWtDTGh1Vkc1UG05em1PaGhVYVRpcFZmbUhCaXBYVU5NcGNXbGljY29fSVUwTzhabmUzSDg3OXk1RS1zc0drUFBPSXJ5WFVyVmZ4RXRVSG92Tk11cFJoVG5sdmFxZTNJdk4wNmQ1VTBGSnNUZ09fbXN4NGpRZEgxYUJzZURPclZ3WnFjNlhaclEwWXBCSGZqdC1QMzNaMXU?oc=5","date":"2026-04-07","type":"trial","source":"Barchart.com","summary":"Influenza Clinical Trial Pipeline Accelerates as 120+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - Barchart.com","headline":"Influenza Clinical Trial Pipeline Accelerates as 120+ Pharma Companies Rigorously Develop Drugs for Market Entry | Delve","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidkFVX3lxTE41T09zSlB1cnM4VHB5NWlfZnlTd0lhYmJSQXdMX0JiS19TbXZzemhoOGlGR2tRODhWUXpvTkl1dkF0NnNOUFIwYjFDTjh4YzJPWDRxOS1TTEVfeW9LZnd0dXJTTFN6WFFObDhxNUM0VEZzcXVzTGc?oc=5","date":"2025-06-17","type":"pipeline","source":"Global Venturing","summary":"Powerlist 2025: Yi Shi - Global Venturing","headline":"Powerlist 2025: Yi Shi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxNSFlQZjVya3VHWUVhbkhFOVFRczNUaUMtUFU5WmFybElkVGM5QWMyc0d0alhJbndMTDAwX1Z2dU1pZm9wb3JOLWtMUnlmM1prcUlIM19vbFJ3cmlJUlRmV0wxXzJBTllOSmJneGh3bDRhZnZVY09pQk9uNnRFLWJ1WGtTeVptR3J6bnEtWEdBNVJQcE9MVmg0TndBaXVTSnVYQ1E?oc=5","date":"2024-05-09","type":"pipeline","source":"BioWorld News","summary":"Flying high with $182M, Bluejay Therapeutics advances BJT-778 - BioWorld News","headline":"Flying high with $182M, Bluejay Therapeutics advances BJT-778","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8gFBVV95cUxPREVjNDZuellFbzZjN0ZQZF9GWktWRnFyc2syMS00X3pzdHFUQ29ONTV1dFA4T0lpekx4LWNZb2dmc3FEaC15R0JnN1MzajBhX1V3cmNFT2NqM0RFNHFvN1JmZ3B4OWRwbzRIRFdmRG1XQ3JIZUZJbHl4UmM3N1JoNjlJV1lxS2lMd0xSeXpLUU56OTc0YkhYQlV3Sk9aS085WGVIVlpvd3djWEVoVnhlR1RMYUdlY0xWQlRLUGdUVjlYSGlnNXQtWWtUcXUtLXpNeFdxNVljX09iRW9OSGRTOXJmQkl1WHM2d2ZjMGJLZ0UyZw?oc=5","date":"2022-11-10","type":"pipeline","source":"PR Newswire","summary":"Lipidio Pharmaceuticals Announces Close of Series A Extension Financing, Bringing Total Round to Over $20M - PR Newswire","headline":"Lipidio Pharmaceuticals Announces Close of Series A Extension Financing, Bringing Total Round to Over $20M","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5gFBVV95cUxQbnFfbDU2Vlc0ZW9BcnItOVEta2p2eVBmM3FaaFFERG5CS0tRd2JBd2ZtWXNOd0lXMEZYNG55LS1SaF82T3ltWDFnV2JVQmQzODJjT0RHSGdDOS1LcGJzemZzV2I2cjI1NnVEV0FFSFBKQXhVT05xZlhQQmxWMGNzTjYyOUtnUHczRGdCaTlCQjdjZ3FpbTZyaXZDdktWeWVKc09feVNtbVc5bEVGS09PR29ZSk52Z0t3UkhvbHFDZ2UtWHh3YklxYk45RUo3c1UtOUVZX0FILVozU1MzZTFfREZaYmo1dw?oc=5","date":"2022-08-31","type":"pipeline","source":"PR Newswire","summary":"Influenza Pipeline Looks Promising as 100+ Companies Working in the Domain, Assesses DelveInsight - PR Newswire","headline":"Influenza Pipeline Looks Promising as 100+ Companies Working in the Domain, Assesses DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxQYmVlVlBlM01zTmJYZmV4RTNBY3J6bDU5R2t3V0tiX0FHbGdPeFYwTDhXQzdXeUplVTRnaHJrRFFxZXJYMFJpUDd3NkdSNnlUMzRVcmVscThnM0J4a1g0anNZN0lGeVUwM214RkJYanBXZ212bFZwNy1MQ1JqeDdkN2VtTQ?oc=5","date":"2022-08-05","type":"pipeline","source":"Fierce Biotech","summary":"Chutes & Ladders—Astellas shakes up leadership with 2 new C-suite execs - Fierce Biotech","headline":"Chutes & Ladders—Astellas shakes up leadership with 2 new C-suite execs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxQOVh0SEhiVlR0R0ZiT0wxM3RDcWx6c1I1Tjk0LWd1TkZFN1pHeHNDMkVId3NxeGo1WmhKQ216OWp0dGRpTlBzdTNHZ3Jlc3BHeUVudFFZR3lMel9NNUxOR00teUg1dWxvcVRWbDdMMWpvdmlkTno5OUhaUG5NZm0ybXhhZWRhZGJfWkp6YlpydTl3S29hYXl3RDI4TDFReDl3bEtEOTh2RzU3ZW5aYVdsQnNrVktueXdXTVlqTHI1dFl3QUl3b0U3Z212OA?oc=5","date":"2020-05-14","type":"pipeline","source":"European Pharmaceutical Review","summary":"Doubt cast over Avigan (favipiravir) and DAS181 potential to fight COVID-19 - European Pharmaceutical Review","headline":"Doubt cast over Avigan (favipiravir) and DAS181 potential to fight COVID-19","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8gFBVV95cUxQS2xPSU1rcUpoWVRqa1laSHZPNEIzYzB5YUM4UmZNeE1WR2szUzZTRGF5a0hpM2RBY2hHLWE2cDhkV1JfZ05nMzJ3azdVbnpNeFB6a3lLVTZCRVJ3UnBGQTVFcTJrSGg1Q2Zzd211LWMzazV0cjJDWEliMmtmUGtodnhrT0s0Tzl1MXBwelc5ZVYwT2dkSjFCWkRISmdxbkdDMnNCNG9KUkRRREM0RHhpUGV2SWNhWEdtd3g0LS10N2psN2ZRZnc4bEFRcF9VbVdTUm04UHk0aU9mQng3dWcwVW43YUprUUh5TVZRX1RBMXFkQQ?oc=5","date":"2020-04-02","type":"trial","source":"PR Newswire","summary":"Ansun Biopharma Announces Positive Results from Investigator-Initiated Trial of Novel COVID-19 Treatment - PR Newswire","headline":"Ansun Biopharma Announces Positive Results from Investigator-Initiated Trial of Novel COVID-19 Treatment","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiwAJBVV95cUxQWkd4bU1fTndzbjFHOEdzTF9mbUZFS3U0LVZlWi1xa052TW5oRU8tbWxYT3pWaXo5c0h0RjBJcl9mQ0c0Q01DeGlUODVwWDJrYjRqdllJenBDeFgwOHpmaTFwTk01cm1TcXdHNjhXMkhWM21EQzVzQmNkQ0NaQkJhbXAzdF94VjJQWXVYV0VvN1BYRjIwVi1fYy1uUUFra0ZvTEpXbGtiNlNfRFJTQlhkNkdOTlhVQkg0UEl1ZmFjTDBSNF80TUJrbEdiUzdmZHRKR1VVcDlNWlFvZHg2cVB3QWhTZm5ZT2lmOHNZQ2x1MkpvUDJJQlpzaVEteGo5dGhOTUp5Nl8tTFBuZFIwSWViNWZRSXplYTBMXzRwNEZGVklacXBqTnNfSmxHSnZoOWoyR2FRNDRja0RPaFZ3ZTB4dg?oc=5","date":"2019-05-28","type":"trial","source":"BioSpace","summary":"Ansun Biopharma Announces First Patient Enrolled In Phase 3 Clinical Trial Evaluating DAS181 In Hospitalized, Immunocompromised Patients With Lower Respiratory Tract Parainfluenza Virus Infection - Bi","headline":"Ansun Biopharma Announces First Patient Enrolled In Phase 3 Clinical Trial Evaluating DAS181 In Hospitalized, Immunocomp","sentiment":"neutral"}],"patents":[],"drugCount":5,"phaseCounts":{"phase_2":2,"phase_3":3},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}